Shulman, David S.
Klega, Kelly
Imamovic-Tuco, Alma
Clapp, Andrea
Nag, Anwesha
Thorner, Aaron R.
Van Allen, Eliezer
Ha, Gavin
Lessnick, Stephen L.
Gorlick, Richard
Janeway, Katherine A.
Leavey, Patrick J.
Mascarenhas, Leo
London, Wendy B.
Vo, Kieuhoa T.
Stegmaier, Kimberly
Hall, David
Krailo, Mark D.
Barkauskas, Donald A.
DuBois, Steven G.
Crompton, Brian D.
Funding for this research was provided by:
Dr. Ha has a patent pending related to genomic technologies that is not directly related to this work.
Dr. Stephen Lessnick holds patents relevant to the diagnosis of Ewing sarcoma
Article History
Received: 4 May 2018
Revised: 9 July 2018
Accepted: 10 July 2018
First Online: 21 August 2018
Change Date: 18 March 2019
Change Type: Correction
Change Details: The authors have noticed that the final paragraph of the Results section contains errors in the number of patients involved. The correct number of patients is included in the text below. These errors do not affect the Figure referenced.In osteosarcoma, we focused on 8q gain as a specific biological feature of interest. Among the 41 patients with detectable ctDNA in the osteosarcoma cohort, 8q gain was detected in 73.2% (30/41). The 3-year EFS for patients with 8q gain (n = 30) in ctDNA was 60.0% (95% CI 40.5–75.0) compared to 80.8 (95% CI 42.4–94.9) in patients without 8q gain (n = 11) in ctDNA (p = 0.18; Fig. 3).
<!--Emphasis Type='Bold' removed-->Ethics approval and consent to participate
: Informed consent for initial collection of samples was obtained at the time each patient enrolled to the approved COG banking studies for Ewing sarcoma and osteosarcoma. The need for additional informed consent for use of banked samples was waived by Dana-Farber Cancer Institute Institutional Review Board.
: This work was supported in part by the National Institutes of Health (NIH) Grant K23 CA154530 (S.G.D.); NIH Grant P30AI027763 to the UCSF-GIVI Center for AIDS Research (UCSF Flow Cytometry Core Laboratory); NIH Grant R01 CA204915 (K.S.); NIH Grand T32 CA136432-08 (D.S.S.); Curing Kids Cancer (K.S.); Alex’s Lemonade Stand Foundation (K.T.V., S.G.D., D.S.S.); Frank A. Campini Foundation (K.T.V., S.G.D.); NIH Grant K08 CA188073-01A1 (B.D.C.); Children’s Oncology Group (COG) Translational Pilot Studies Program for Solid Malignancies (B.D.C.); Boston Children’s Hospital Translational Research Program (B.D.C.); Pediatric Cancer Research Foundation (B.D.C.); Go 4 The Goal Foundation (B.D.C.); QuadW Foundation (D.H., M.D.K., D.A.B.); and the following support to COG: St. Baldrick’s Foundation, U10CA180884, U10CA180886, U10CA180899, U10CA098543, U10CA098413, and U24CA114766 (COG). The contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH or other funding agencies.
: Dr. Lessnick holds patents related to the diagnosis of Ewing sarcoma. Dr. Ha has a pending patent relevant to genomic technologies. The other authors declare no competing interests.
: All data are stored locally at the Dana-Farber Cancer Institute and can be made available upon request.
: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).